title: Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy.
authors.affiliation: Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut.
authors.forename: Kathleen C
authors.initials: KC
authors.lastname: Suozzi
authors.affiliation: Department of Medicine, Yale University School of Medicine, New Haven, Connecticut.
authors.forename: Maximilian
authors.initials: M
authors.lastname: Stahl
authors.affiliation: Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut.
authors.forename: Christine J
authors.initials: CJ
authors.lastname: Ko
authors.affiliation: Department of Medicine, Yale University School of Medicine, New Haven, Connecticut; Smilow Cancer Center, Yale University School of Medicine, New Haven, Connecticut.
authors.forename: Anne
authors.initials: A
authors.lastname: Chiang
authors.affiliation: Department of Medicine, Yale University School of Medicine, New Haven, Connecticut; Smilow Cancer Center, Yale University School of Medicine, New Haven, Connecticut.
authors.forename: Scott N
authors.initials: SN
authors.lastname: Gettinger
authors.affiliation: Department of Medicine, Yale University School of Medicine, New Haven, Connecticut.
authors.forename: Mark D
authors.initials: MD
authors.lastname: Siegel
authors.affiliation: Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut.
authors.forename: Christopher G
authors.initials: CG
authors.lastname: Bunick
keywords: CTLA-4, cytotoxic T-lymphocyte–associated antigen 4; PD-1, programmed death–1; immune-related adverse events; immunotherapy; irAEs, immune-related adverse events; lung cancer; sarcoidosis